Smoking, Sex, and Non–Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424)
Open Access
- 13 January 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 110 (7) , 734-742
Abstract
To what extent steroid hormones contribute to lung cancer in male and female never smokers and smokers is unclear. We examined expression of hormone receptors in lung tumors by sex and smoking. Patients with primary non–small cell lung cancer were recruited into an Intergroup study in the United States and Canada, led by SWOG (S0424). Tumors from 813 cases (450 women and 363 men) were assayed using immunohistochemistry for estrogen receptor (ER)–α, ER-β, progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Linear regression was used to examine differences in expression by sex and smoking status. Cox proportional hazard models were used to estimate survival associated with the receptors. All statistical tests were two-sided. In ever smokers, postmenopause and oral contraceptive use were associated with lower nuclear ER-β (P = .02) and total (nuclear + cytoplasmic) PR expression (P = .02), respectively. Women had lower cytoplasmic ER-α (regression coefficient [β], or differences in H-scores = –15.8, P = .003) and nuclear ER-β (β = –12.8, P = .04) expression than men, adjusting for age, race, and smoking. Ever smokers had both higher cytoplasmic ER-α (β = 45.0, P < .001) and ER-β (β = 25.9, P < .001) but lower total PR (β = –42.1, P < .001) than never smokers. Higher cytoplasmic ER-α and ER-β were associated with worse survival (hazard ratio = 1.73, 95% confidence interval [CI] = 1.15 to 2.58, and HR = 1.59, 95% CI = 1.08 to 2.33, respectively; quartiles 4 vs 1). Lower expression of nuclear ER-β in women supports the estrogen hypothesis in lung cancer etiology. Increasing cytoplasmic ER-α and ER-β and decreasing PR protein expression may be mechanisms whereby smoking disrupts hormone pathways.Keywords
Funding Information
- National Cancer Institute at the National Institutes of Health (R01CA106815, U10CA180888, U10CA180819, UG1CA189974, U10CA180799, U10CA180820, U10CA180821, U10CA180868, P30CA016056, K07CA201334)
- National Institute of Environmental Health Sciences
- National Institutes of Health (P30ES009089)
- Breast Cancer Research Foundation
This publication has 43 references indexed in Scilit:
- Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant dataThe Lancet, 2013
- Combined Analysis of Estrogen Receptor β-1 and Progesterone Receptor Expression Identifies Lung Cancer Patients with Poor OutcomeClinical Cancer Research, 2011
- Reproductive Factors, Hormone Use, and Risk for Lung Cancer in Postmenopausal Women, the Nurses' Health StudyCancer Epidemiology, Biomarkers & Prevention, 2010
- Lung Cancer Among Postmenopausal Women Treated With Estrogen Alone in the Women's Health Initiative Randomized TrialJNCI: Journal of the National Cancer Institute, 2010
- Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trialThe Lancet, 2009
- Immunohistochemical Expression of Estrogen and Progesterone Receptors Identifies a Subset of NSCLCs and Correlates with EGFR MutationClinical Cancer Research, 2009
- Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort studyThe Lancet Oncology, 2008
- Aromatase Expression Predicts Survival in Women with Early-Stage Non–Small Cell Lung CancerCancer Research, 2007
- Differential Ligand Activation of Estrogen Receptors ERα and ERβ at AP1 SitesScience, 1997
- Checking the Cox model with cumulative sums of martingale-based residualsBiometrika, 1993